Syntekabio will present its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) on August 19, 2022, in Arlington, VA. Dr. Kilyoung Kim will discuss the company’s innovative advancements, fostering collaboration between American and Korean professionals in technology and entrepreneurship.
Syntekabio, a pioneering AI drug discovery and development company, is set to unveil its novel AI-driven cloud platforms, DeepMatcher® and NEO-ARS™, at the upcoming US-Korea Conference (UKC) scheduled for August 19, 2022. This prestigious event, taking place in Arlington, Virginia, will host a diverse audience from the U.S. and Korea, fostering collaboration in the fields of science, engineering, and technology. Analysis and discussions during the Innovative and Entrepreneurship Symposium (IES) offer companies the opportunity to showcase their innovative technologies aimed at stimulating cross-border business ventures. Dr. Kilyoung Kim, Chief Scientific Officer and President of Syntekabio USA, will be representing the company at the symposium, providing insights into their latest advancements in AI drug discovery. Media representatives are encouraged to schedule meetings for further discussions post-presentation.
Established in 2009 and headquartered in South Korea, Syntekabio specializes in utilizing artificial intelligence and big data for drug discovery and development. The company is at the forefront of integrating innovative technologies into the pharmaceutical industry to address global health challenges effectively. The upcoming launch of DeepMatcher® and NEO-ARS™, slated for September 2022, aims to enhance drug development processes by leveraging sophisticated AI algorithms.
In conclusion, Syntekabio’s participation in the US-Korea Conference represents a significant stride toward advancing global health solutions through innovative AI technologies. The launch of the DeepMatcher® and NEO-ARS™ platforms promises to revolutionize drug discovery and development, enabling the company to contribute meaningfully to healthcare improvements worldwide. Stakeholders attending the symposium will gain valuable insights into these groundbreaking technologies.
Original Source: www.globenewswire.com
